Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576938 · ClinicalTrials.gov registry record · Phase 2
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT02576938: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT02576938 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 124 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02576938, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.
Primary Outcome
The EASI 50, defined as ≥ 50% reduction from baseline in EASI score, assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe.
Interventions
- DRUG Placebo
- DRUG Baricitinib
- DRUG Triamcinolone (Optional)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
What the finished NCT02576938 record still lists
NCT02576938 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02576938 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02576938 about?
NCT02576938 is a clinical study titled "A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis". The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.
What is the current status of trial NCT02576938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2016-02. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02576938?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG), Triamcinolone (Optional) (DRUG).
Who is sponsoring clinical trial NCT02576938?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02576938's enrollment target sits among peer trials
124 564th of 2000 higher than 1,437 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia